Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of BOTOX for prevention of episodic migraine in adults
MOH_2021-11-03_010261Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in episodic migraine (3 arms), sponsored by AbbVie Inc. Started Sep 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
episodic migraine
Beyond the preview
Go deeper on MOH_2021-11-03_010261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-03_010261.